$15.66
-0.09-0.57%
Last update: Nov 9, 9:29 AM
Rallybio Corp
RLYBNASDAQ
Rallybio rose 201.2% from $5.20 to $15.66, ahead of the S&P 500's +10.5%. Its worst day was Feb 17 (−10.2%), and its low came Feb 17 at $4.33.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Rallybio closed at its lowest level of the year, 16.7% below where the year started.
−10.2%, the year's worst day · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
Rallybio shares rose 45.5%, while the S&P 500 rose 0.1%.
+45.5% · S&P 500 +0.1%
EPS of $-1.03 beat the $-1.14 estimate on $222,000.00 revenue (est. $133,330.00).
−0.9% · S&P 500 +1.0%
Rallybio shares rose 50.1%, while the S&P 500 fell 0.4%.
+50.1%, the year's best day, on 11M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $-1.46 missed the $-1.20 estimate on $212,000.00 revenue.
−1.0% · S&P 500 +0.8%
Rallybio shares rose 16.7%, while the S&P 500 rose 0.3%.
+16.7% · S&P 500 +0.3%
EPS of $-0.84 beat the $-1.28 estimate on $0.00 revenue.
+0.3% · S&P 500 −0.2%
Rallybio closed at its highest level of the year, 231.2% above where the year started.
+4.3% · S&P 500 −0.5%
EPS of $-0.48 beat the $-1.44 estimate on $0.00 revenue.
−3.0% · S&P 500 +0.6%
Where it ended: a close of $15.66 on Nov 9, 2026.
Nothing in the past 12 months.
All RLYB analyst actionsNothing in the past 12 months.
All RLYB dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RLYB and SPY from Benzinga historical bars. Not investment advice.
